TARGETED RADIOTHERAPY: MICROGRAY DOSES AND THE BYSTANDER EFFECT by Mairs, Robert J et al.
Dose-Response: An International Journal
Volume 5 | Issue 3 Article 6
9-2007
TARGETED RADIOTHERAPY: MICROGRAY
DOSES AND THE BYSTANDER EFFECT
Robert J Mairs
Glasgow University, Cancer Research UK Beatson Laboratories, Glasgow, UK
Natasha E Fullerton
Glasgow University, Cancer Research UK Beatson Laboratories, Glasgow, UK
Michael R Zalutsky
Duke University Medical Centre, Durham, NC, USA
Marie Boyd
Glasgow University, Cancer Research UK Beatson Laboratories, Glasgow, UK
Follow this and additional works at: https://scholarworks.umass.edu/dose_response
This Article is brought to you for free and open access by ScholarWorks@UMass Amherst. It has been accepted for inclusion in Dose-Response: An
International Journal by an authorized editor of ScholarWorks@UMass Amherst. For more information, please contact
scholarworks@library.umass.edu.
Recommended Citation
Mairs, Robert J; Fullerton, Natasha E; Zalutsky, Michael R; and Boyd, Marie (2007) "TARGETED RADIOTHERAPY:
MICROGRAY DOSES AND THE BYSTANDER EFFECT," Dose-Response: An International Journal: Vol. 5 : Iss. 3 , Article 6.
Available at: https://scholarworks.umass.edu/dose_response/vol5/iss3/6
204
TARGETED RADIOTHERAPY: MICROGRAY DOSES AND THE BYSTANDER
EFFECT 
Robert J. Mairs, Natasha E. Fullerton*  Targeted Therapy Group, Division of
Cancer Science and Molecular Pathology, Glasgow University, Cancer Research UK
Beatson Laboratories, Glasgow, UK
Michael R. Zalutsky  Department of Radiology, Duke University Medical
Centre, Durham, North Carolina, USA
Marie Boyd  Targeted Therapy Group, Division of Cancer Science and
Molecular Pathology, Glasgow University, Cancer Research UK Beatson
Laboratories, Glasgow, UK
 Indirect effects may contribute to the efficacy of radiotherapy by sterilizing malignant
cells that are not directly irradiated. However, little is known of the influence of indirect
effects in targeted radionuclide treatment. We compared γ-radiation-induced bystander
effects with those resulting from exposure to three radiohaloanalogues of meta-iodoben-
zylguanidine (MIBG): [131I]MIBG (low linear energy transfer (LET) β-emitter),
[123I]MIBG (high LET Auger electron emitter), and meta-[211At]astatobenzylguanidine
([211At]MABG) (high LET α-emitter). Cells exposed to media from γ-irradiated cells
exhibited a dose-dependent reduction in survival fraction at low dosage and a plateau in
cell kill at > 2 Gy. Cells treated with media from [131I]MIBG demonstrated a dose-response
relationship with respect to clonogenic cell death and no annihilation of this effect at high
radiopharmaceutical dosage. In contrast, cells receiving media from cultures treated with
[211At]MABG or [123I]MIBG exhibited dose-dependent toxicity at low dose but elimination
of cytotoxicity with increasing radiation dose (i.e. U-shaped survival curves). Therefore
radionuclides emitting high LET radiation may elicit toxic or protective effects on neigh-
boring untargeted cells at low and high dose respectively. We conclude that radiophar-
maceutical-induced bystander effects may depend on LET and be distinct from those
elicited by conventional radiotherapy. 
Keywords: Radiopharmaceutical-induced bystander effect
I. INTRODUCTION
When cells are exposed to ionizing radiation, they release poisons
which result in death, mutation, chromosomal aberrations or long term
genomic instability in neighboring, unirradiated cells (Mothersill and
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Seymour 2001; Mothersill and Seymour 2004; Lyng et al 2002; Lorimore
and Wright 2003; Morgan 2003; Little 2003). These consequences, known
as radiation induced biological bystander effects (RIBBE), may con-
tribute significantly to the effectiveness of radiotherapy by sterilising
malignant cells which have not been directly irradiated. 
In recent years, targeted radionuclide treatment of cancer has devel-
oped as a novel and advantageous approach to radiation therapy. The
basic idea is to deliver higher doses of radiation to tumor than to normal
cells by means of radionuclides chemically conjugated to tumor-seeking
targeting agents such as meta-iodobenzylguanidine (MIBG). By virtue of
its structural similarity to noradrenaline (Wieland et al 1980), MIBG is
selectively accumulated via the noradrenaline transporter (NAT)
(Jacques et al 1984) which is expressed on the surfaces of cells comprising
tumors of neural crest origin, for example neuroblastoma and phaeo-
chromocytoma. Radiolabelled forms of this drug are used for scinti-
graphic assessment and treatment of such tumors (Simpson and Gaze
1998; Klingebiel et al 1998; Hoefnagel 1999; Rose et al 2003). NAT expres-
sion is predictive for MIBG uptake capacity (Mairs et al 1994) and quan-
tification of NAT mRNA could be used for the selection of patients for
MIBG therapy (Carlin et al 2003).
It may be possible to compensate for heterogeneity of uptake of radio-
pharmaceutical, resulting in underdosing of some tumor regions, by the
selection of radionuclides whose decay particles have long path lengths,
enabling cross-fire irradiation of surrounding untargeted cells. However,
even with long range radionuclides, because their emissions are of low
LET, sub-populations of tumor cells will receive less than a sterilizing dose.
Then again, emerging evidence suggests that radioactive emission from
targeted cells is not the only bystander effect operating in radionuclide
treatment of cancer. It is becoming clear that radiation-induced biological
bystander effects (RIBBE) deriving from the cellular processing of the
physical radiation insult, which need not interact directly with DNA, may
play an important part in the overall efficacy of radionuclide targeting.
RIBBE predominate at low radiation dose and low dose rate (Carlsson
et al 2003) both of which are features of targeted radionuclide treatment
of cancer. Therefore bystander effects induced by radiopharmaceuticals
may play a disproportionate role in the efficacy, and understanding their
nature should enable the refinement of radiotherapy. Most investigations
of bystander effects have involved external beam γ-irradiators and
microbeams. However, in recent years important studies have been con-
ducted of RIBBE after intracellular concentration of radiolabelled drugs.
Bishayee et al (2001) prepared clusters composed of unlabelled and
[3H]thymidine-labelled cells. The resulting death of unlabelled cells was
considered to be a consequence of transfer of toxic factors from cells
which had incorporated [3H]thymidine in their DNA rather than cross-
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fire irradiation because 3H beta-decay particles have a path length which
is too short to allow direct bombarment of regions adjacent to targeted
cells. Survival of unlabelled cells was increased by treatment with
dimethyl sulphoxide and lindane, suggesting the involvement of free rad-
icals and gap junctional communication respectively. In a similar study,
Xue et al (2002) mixed colon carcinoma cells, unlabelled or incubated
with the thymidine analogue [125I]IUDR, and used these mixtures to
form subcutaneous tumors in athymic mice. Again, inhibition of tumor
growth was attributed to RIBBE because the range of 125I Auger electrons
is insufficient to interact directly with neighboring cells. 
Here we describe bystander responses following the uptake of radio-
haloanalogues of MIBG by NAT gene-transfected tumor cell lines. Our
results provide further insight into the dependence of targeted radio-
therapy on RIBBE and the influence of radiation quality.
II. TRANSFECTANT MOSAIC SPHEROIDS: A NEW MODEL FOR
EVALUATION OF TUMOR CELL KILLING IN TARGETED RADIOTHERAPY
AND GENE THERAPY
An attractive characteristic of therapeutic strategies which combine
gene manipulation with the administration of radiopharmaceuticals is
cross-fire irradiation of non-transfected cells. We assessed the usefulness
of this effect using our recently developed mosaic spheroid model (Boyd
and Mairs 2004) composed of mixtures of transfected and untransfected
cells (Boyd et al 2002) (Figure 1). This allowed our evaluation of the min-
imum percentage of transfection required to achieve cure of different
sizes of metastases. For example: modest radioactivity concentrations
(20 kBq/ml) of [211At]MABG induced the complete sterilisation of
FIGURE 1. Fluorescent confocal microscopic images of optical sections through a transfected mosa-
ic spheroid composed of 50% NAT-expressing cells and 50% GFP-expressing cells. (A) phase contrast
image of an equatorial optical section showing all cells present within the spheroid; (B) GFP-express-
ing cells only; (C) merged image showing GFP-labelled cells superimposed upon the phase contrast
image.
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250μm diameter mosaic spheroids composed of only 5% NAT gene trans-
fectants (Figure 2). Because the path length of 211At α-particles is only 55
to 70 μm, cross-fire irradiation from targeted to untargeted cells would be
considerably less extensive than that from a β-emitter such as 131I.
Therefore this observation suggests that bystander effects, over and above
cross-fire irradiation, are operating in α-particle targeted therapy.
These studies indicate the potential for bystander-mediated cell kill
and improved clinical efficacy of tumor targeting when only a small pro-
portion of the tumor mass expresses the radiotherapeutic molecular tar-
get, in this case, introduced via gene modification. Moreover, RIBBE
could compensate for the low levels of gene delivery currently achievable
in vivo in cancer gene therapy strategies when married with targeted
radionuclide therapy. Rational selection of radiohaloconjugates of MIBG
will enable the enhancement of cross-fire kill to maximize neuroblastoma
cell kill. 
III. MEDIA TRANSFER METHOD FOR ASSESSMENT OF RIBBE 
Our procedure for determining bystander responses in vitro employs
an adaptation of the media transfer system developed by Mothersill and
Seymour (1997) to compare the induction of bystander effects by exter-
nal beam γ-radiation with those generated by MIBG labelled with radio-
nuclides emitting β-particles, α-particles, or Auger electrons (Boyd et al
2006). The cells used in these experiments were transfected with the NAT
gene to facilitate the active uptake of radiolabeled MIBG. Similarly treat-
ed control cells were untransfected and hence incapable of concentra-
tion of the radiopharmaceutical. This allowed our determination of the
FIGURE 2. Toxcity, measured by clonogenic assay, of [211At]MABG to UVW spheroids containing
various percentages of NAT gene-transfected cells. Means and standard deviations of triplicate
determinations.
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requirement for intracellular accumulation of radionuclide for induction
of RIBBE.
For investigation of RIBBE following γ-irradiation, donor cells were
directly irradiated and their medium was transferred to recipient cells
which were not directly irradiated. Separate cultures (termed “direct”)
were directly irradiated and their medium was not removed.
Consequently the direct cells experienced the physical and biological
effects of the radiation treatment. For the evaluation of RIBBE in radio-
pharmaceutical-treated cells, it was necessary to control for killing of
recipient cells due to the transfer of radiopharmaceutical effluxed from
donor cells. To cultures, designated activity controls, was administered
radiopharmaceutical activity equivalent to that which had leaked from
donor cultures and would have been transferred to recipient cells. 24 h
after these manipulations, cell kill was determined by clonogenic assay
(Figure 3).
IV. RIBBE INDUCED BY γ-IRRADIATION AND TARGETED RADIOPHAR-
MACEUTICALS
We observed that exposure of two human tumor cell lines—UVW
glioma and EJ138 bladder carcinoma—to media derived from external
beam irradiated cells produced a dose-dependent reduction in survival
FIGURE 3. Media transfer method for assessing bystander effect after radiopharmaceutical treat-
ment of cultured cells.
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fraction in the dose range 0 to 2 Gy, followed by a plateau in clonogenic
cell kill at levels greater than 2 Gy (Figure 4). Similarly, other reports of
media transfer experiments, following treatment with γ-rays or soft x-rays,
have indicated that the dose-response in bystander cells reached a plateau
at low doses (Mothersill and Seymour 1997; Seymour and Mothersill
2000; Belyakov et al 2001).
In contrast, no such plateau with respect to clonogenic cell kill was
evident in recipients of medium from NAT-expressing cells incubated
with [131I]MIBG (Figure 5). The potency of RIBBE produced by NAT-
expressing cells after treatment with Auger electron emitting [123I]MIBG
or α-particle emitting [211At]MABG, increased with activity up to levels
which resulted in a direct kill of 35 to 45% (EJ cells) or 60 to 70% (UVW
cells) of clonogens. At higher activity concentrations of [123I]MIBG or
FIGURE 4. Survival of UVW/NAT cells (A) and EJ138/NAT cells (B) following treatment with γ-radi-
ation (direct) or medium from irradiated cells (recipient). Means and standard deviations of six
experiments performed in triplicate.
FIGURE 5. Survival of UVW/NAT cells (A) and EJ138/NAT cells (B) following treatment with
[131I]MIBG (direct) or medium from [131I]MIBG-treated cells (recipient). Cultures designated activ-
ity control received radiopharmaceutical activity equivalent to that which had leaked from donor cul-
tures and would have been transferred to recipient cells. Means and standard deviations of six exper-
iments performed in triplicate.
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[211At]MABG, RIBBE became progressively weaker (Figure 6). The U-
shaped survival curves associated with intracellularly concentrated high-
LET emitters suggest that, after intracellular bombardment, the RIBBE-
generating apparatus is inhibited above a threshold radiation dose. The
RIBBE elicited by the pre-nadir activity range of these high LET targeted
radionuclides resulted in a magnitude of cell kill similar to that caused by
direct irradiation, indicating that bystander effects may be significant
contributors to the cytotoxicity of [123I]MIBG and [211At]MABG at low
activity concentrations. It will be important to the development of tumor
targeting by [125I]- and [211At]-labeled compounds to determine differ-
ences in the nature of toxins generated at low (pre-nadir) and high (post-
nadir) radioactivity concentrations. 
Significantly, neither direct nor indirect kill was observed at any activ-
ity concentration in cultures of cells which did not express the NAT and
were incapable of active uptake of MIBG. Thus, these RIBBE effects were
not related to decays of unbound radiopharmaceutical present in the
media. These findings suggest that potent toxins are generated specifi-
cally by cells which concentrate targeted radionuclides. Furthermore, a
comparison of the dose dependence of these effects with those observed
FIGURE 6. Survival of UVW/NAT cells [(A) and (B)] and EJ138/NAT cells [(C) and (D)] following
treatment with [123I]MIBG and [211At]MABG (direct) respectively or medium from radiopharma-
ceutical-treated cells (recipient). Cultures designated activity control received radiopharmaceutical
activity equivalent to that which had leaked from donor cultures and would have been transferred to
recipient cells. Means and standard deviations of six experiments performed in triplicate.
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after exposure to γ-rays suggests that RIBBE effects from targeted radio-
therapeutics may be distinct from those elicited by conventional external
beam radiotherapy.
V. CONCLUSION
The successful application of targeted radionuclide cancer therapy is
critically dependent on the delivery of cytotoxic doses of radiation to the
vast majority of the malignant cell population. Achieving this goal can be
confounded by multiple factors, including variations in target molecule
expression and tumor hemodynamic parameters, that can lead to het-
erogeneity in radiopharmaceutical delivery, retention or binding.
However, it has been widely appreciated that cells not accumulating the
labelled molecule can be killed as a result of being hit by radiation emit-
ted from neighboring cells. Consideration of this process, known as the
(physical) bystander effect, has played an important role in the design of
radiotherapeutic strategies, for example, the selection of long range β-
particle emitters in situations where heterogeneous radiopharmaceutical
delivery is anticipated.
A second type of bystander effect that could have important implica-
tions for targeted radionuclide therapy is the radiation induced biologi-
cal bystander effect (RIBBE), which results in the killing of cells not
directly exposed to radiation. The mechanisms involved are as yet unde-
fined. However, studies using γ-ray and α-particle beams have provided
some insight into possible factors. These include oxidative stress leading
to increased radical formation (Lehnert and Goodwin 1997; Narayanan
et al 1997) nitric oxide release (Matsumoto et al 2001; Shao et al 2002)
cytokine release (Iyer and Lehnert 2000) and gap junctional intracellular
communication (Azzam et al 2001). RIBBE resultant from targeted
radionuclides has largely been unexplored and the effects of radiation
quality remain unknown (Mairs and Boyd 2005).
Elucidation of the pathways involved in RIBBE generation by
radionuclides could indicate ways of manipulating RIBBE production to
reduce toxicity to normal tissues which are inadvertently irradiated dur-
ing the course of a targeted radiotherapy regime. Careful choice of
radionuclides and dose administered in clinical scenarios for targeted
radionuclide therapy of tumors which naturally accumulate targeted
radionuclides or have been genetically manipulated to do so, will allow
factors such as inefficient gene transfer and heterogeneous uptake to be
compensated for, thus optimising the cell kill potential of this therapeu-
tic scheme.
Whatever the mechanism, RIBBE could be important not only in rela-
tion to radiation protection and safety but also with respect to the thera-
peutic use of ionizing radiation. Exploitation of RIBBE could be espe-
cially relevant to the efficacy of targeted radiotherapy because this treat-
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ment is limited by heterogeneous uptake of radionuclides by tumors.
Freely diffusible toxic bystander signals could overcome the inefficiency
of tumor control due to non-uniform distribution of radiation dose. 
We seek now to investigate the nature of RIBBE signals generated by
radiopharmaceuticals localized to different sub-cellular regions. The effi-
ciency of this mode of kill in tumor and normal cells and its possible
dependence on genetic background and tumor microenvironment must
also be assessed. From a practical perspective, the identification of RIBBE
factors will stimulate the design of strategies to maximize damage to
tumor cells while minimizing damage to normal cells.
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